· Laquinimod - a clinical trial is planned prior to filing an NDA in the US
· TASQ - an investigator-sponsored Phase I clinical trial launched
- enrolment of patients for Phase III trial proceeding according to plan
· ANYARA - Phase III trial continuing according to plan
· 57-57 - a clinical trial in systemic sclerosis/scleroderma initiated
· ISI - project is proceeding as planned
· RhuDex® - a Phase I clinical formulation study launched
· Focusing of the operation; notice of termination of employment to 25 staff members
· Net sales SEK 234.6 M (11.4)
· Operating loss SEK 100.9 M (Loss: 229.0)
· Loss after tax SEK 94,5 M (Loss: 221.1)
· Loss per share for the period was SEK 1.38 (Loss: 3.38)
For further information, please contact:
Tomas Leanderson
President and CEO
Tel +46 (0)46-19 20 95
Hans Kolam
CFO
Tel +46 (0)46-19 20 44
Active Biotech AB (Corp. Reg. No. 556223-9227)
PO Box 724, SE-220 07 Lund
Tel +46 (0)46-19 20 00
Fax +46 (0)46-19 11 00
This report is also available at www.activebiotech.com
